Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Basit Öğe Kaydı
dc.authorscopusid57915800400
dc.authorscopusid56497709600
dc.authorscopusid58922169000
dc.authorscopusid58146204100
dc.authorscopusid36084956000
dc.authorscopusid57215586547
dc.authorscopusid59147681500
dc.contributor.authorAkyildiz A.
dc.contributor.authorGuven D.C.
dc.contributor.authorKoksal B.
dc.contributor.authorKaraoglan B.B.
dc.contributor.authorKivrak D.
dc.contributor.authorIsmayilov R.
dc.contributor.authorAslan F.
dc.date.accessioned2024-06-12T10:24:57Z
dc.date.available2024-06-12T10:24:57Z
dc.date.issued2024
dc.description.abstractObjectives: Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial. This study aimed to evaluate the real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. Design: In this multicenter retrospective study, we analyzed 124 patients with recurrent or metastatic non-nasopharyngeal HNC who received nivolumab in the second-line setting and beyond. Data were collected from 20 different cancer centers across Turkey. The effectiveness and safety of the treatment and survival outcomes were evaluated. Results: Nivolumab exhibited favorable clinical responses, yielding an objective response rate of 29.9% and a disease control rate of 55.7%. Safety assessments revealed a generally well-tolerated profile, with no instances of treatment discontinuation or mortality due to side effects. Survival analysis disclosed a median overall survival (OS) of 11.8 (95% CI 8.4–15.2) months. Multivariate analysis revealed that ECOG-PS ? 1 (HR: 1.64, p = 0.045), laryngeal location (HR: 0.531, p = 0.024), and neutrophil-to-lymphocyte ratio > 3.5 (HR: 1.97, p = 0.007) were independent predictors of OS. Conclusions: Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes. © The Author(s) 2024.en_US
dc.description.sponsorshipTürkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAKen_US
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Council of T\u00FCrkiye (T\u00DCB\u0130TAK). The authors received no financial support for this article.en_US
dc.identifier.doi10.1007/s00405-024-08744-4
dc.identifier.issn0937-4477
dc.identifier.pmid38795147en_US
dc.identifier.scopus2-s2.0-85194398073en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s00405-024-08744-4
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16110
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.ispartofEuropean Archives of Oto-Rhino-Laryngologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHead And Neck Cancer; Nivolumaben_US
dc.titleReal-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu